Unsupervised Hierarchical Clustering of Surface Antigen Expression to Identify Patients with Normal Karyotype AML with Distinct Disease Characteristics and Poor Outcome
Improved Survival with Fludarabine and Timed Sequential Busulfan Regimen in Older Patients with AML or MDS
Allogeneic Transplant Leads to Markedly Improved Survival in Older Patients with Acute Myeloid Leukemia
Evaluation of Minimal Residual Disease in Relapsed/Refractory Multiple Myeloma Patients Treated with a Daratumumab-Based Regimen
In this analysis, researchers evaluate whether daratumumab can further reduce minimal residual disease when added to lenalidomide- and bortezomib-containing regimens in patients with relapsed/refractory multiple myeloma.
Meta-Analysis to Compare Efficacy of Treatment Regimens for Relapsed/Refractory Multiple Myeloma Patients
Phase II Study of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma
In an effort to determine whether lower peripheral neuropathy rates could be achieved, this study evaluated the efficacy and safety of subcutaneous bortezomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Budget Impact Analysis of Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Payers have expressed concern about the rising costs of combination therapies in multiple myeloma. In an effort to address these potential concerns, a budget impact model was developed to estimate the 3-year costs of adding elotuzumab in combination with lenalidomide and dexamethasone to a health plan’s formulary.
A New Risk Stratification Tool to Estimate Survival in Patients with Multiple Myeloma After First Relapse
Risk stratification tools are used to estimate survival expectations and help to guide treatment decisions after first relapse in multiple myeloma. European researchers have developed a new stratification tool consisting of 4 distinct dimensions that are used to characterize risk of survival.
Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Immunotherapy is being studied as a potential treatment approach in a variety of hematologic malignancies. Here, researchers present the findings of a phase 2 trial evaluating pembrolizumab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Page 12 of 16
Results 111 - 120 of 153
Results 111 - 120 of 153